S4V2 / LimmaTech Biologics, Valneva, Eli Lilly - LARVOL DELTA

S4V03: A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: LimmaTech Biologics AG | Recruiting ➔ Active, not recruiting

Enrollment closed

S4V02: Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants. (clinicaltrials.gov) - P2 | N=110 | Completed | Sponsor: LimmaTech Biologics AG | Active, not recruiting ➔ Completed

Trial completion

S4V02: Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants. (clinicaltrials.gov) - P2 | N=110 | Active, not recruiting | Sponsor: LimmaTech Biologics AG | Recruiting ➔ Active, not recruiting

Enrollment closed

S4V03: A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: LimmaTech Biologics AG | Trial completion date: Dec 2025 ➔ Jul 2026 | Trial primary completion date: Jul 2025 ➔ Feb 2026

Trial completion date • Trial primary completion date

S4V02: Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants. (clinicaltrials.gov) - P2 | N=110 | Recruiting | Sponsor: LimmaTech Biologics AG | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2025 ➔ Feb 2026 | Trial primary completion date: May 2025 ➔ Oct 2025

Enrollment open • Trial completion date • Trial primary completion date

S4V02: Study to Expand Safety and Immunogenicity Data with Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants. (clinicaltrials.gov) - P2 | N=110 | Not yet recruiting | Sponsor: LimmaTech Biologics AG | Initiation date: Nov 2024 ➔ Feb 2025

Trial initiation date

S4V03: A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: LimmaTech Biologics AG | Trial primary completion date: Oct 2025 ➔ Jul 2025

Trial primary completion date

S4V03: A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: LimmaTech Biologics AG | Not yet recruiting ➔ Recruiting

Enrollment open

S4V03: A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: LimmaTech Biologics AG

New P2 trial

S4V02: Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants. (clinicaltrials.gov) - P2 | N=110 | Not yet recruiting | Sponsor: LimmaTech Biologics AG

New P2 trial